Literature DB >> 16104638

Multicenter study of MTT and resazurin assays for testing susceptibility to first-line anti-tuberculosis drugs.

A Martin1, N Morcillo, D Lemus, E Montoro, M A da Silva Telles, N Simboli, M Pontino, T Porras, C León, M Velasco, L Chacon, L Barrera, V Ritacco, F Portaels, J C Palomino.   

Abstract

OBJECTIVE: A multicentre evaluation was performed to assess two rapid low-cost methods, MTT (3-[4.5-dimethylthiazol-2-yl]-2.5-diphenyltetrazolium bromide) and resazurin assays, for testing the susceptibility of Mycobacterium tuberculosis to the first-line anti-tuberculosis drugs rifampicin (RMP), isoniazid (INH), ethambutol (EMB) and streptomycin (SM).
METHODS: Thirty coded M. tuberculosis strains were sent to seven laboratories located in Latin America, representing six countries. Each site performed the colorimetric assays, MTT and resazurin, blind for the first-line drugs RMP, INH, EMB and SM. The minimum inhibitory concentration results obtained were compared to the conventional proportion method on Lowenstein-Jensen medium.
RESULTS: After establishing the breakpoint concentrations, excellent results were obtained for RMP, INH and EMB, with levels of specificity and sensitivity of between 96% and 99%.
CONCLUSION: MTT and resazurin assays are promising, accessible new alternative methods for middle- and low-resource countries that need low-cost methods to perform rapid susceptibility testing of M. tuberculosis to key anti-tuberculosis drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16104638

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  31 in total

1.  Safety of upper-room ultraviolet germicidal air disinfection for room occupants: results from the Tuberculosis Ultraviolet Shelter Study.

Authors:  Edward A Nardell; Scott J Bucher; Philip W Brickner; Charles Wang; Richard L Vincent; Kathleen Becan-McBride; Mark A James; Max Michael; James D Wright
Journal:  Public Health Rep       Date:  2008 Jan-Feb       Impact factor: 2.792

2.  Use of colorimetric culture methods for detection of Mycobacterium tuberculosis complex isolates from sputum samples in resource-limited settings.

Authors:  Yap Boum; Patrick Orikiriza; Gabriel Rojas-Ponce; Margarita Riera-Montes; Daniel Atwine; Margaret Nansumba; Joel Bazira; Eleanor Tuyakira; Pierre De Beaudrap; Maryline Bonnet; Anne-Laure Page
Journal:  J Clin Microbiol       Date:  2013-05-08       Impact factor: 5.948

3.  Resazurin Microtiter Assay for Clarithromycin Susceptibility Testing of Clinical Isolates of Mycobacterium abscessus Group.

Authors:  Natalia Fernandes Garcia de Carvalho; Daisy Nakamura Sato; Fernando R Pavan; Lucilaine Ferrazoli; Erica Chimara
Journal:  J Clin Lab Anal       Date:  2016-05-12       Impact factor: 2.352

4.  Coresistance to isoniazid and ethionamide maps to mycothiol biosynthetic genes in Mycobacterium bovis.

Authors:  Catherine Vilchèze; Yossef Av-Gay; S Whitney Barnes; Michelle H Larsen; John R Walker; Richard J Glynne; William R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

Review 5.  General and advanced diagnostic tools to detect Mycobacterium tuberculosis and their drug susceptibility: a review.

Authors:  Md A Gazi; Md R Islam; Mohammad G Kibria; Z Mahmud
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-01-06       Impact factor: 3.267

6.  The combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosis.

Authors:  Catherine Vilchèze; William R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2012-07-23       Impact factor: 5.191

7.  Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions.

Authors:  Catherine Vilchèze; Anthony D Baughn; JoAnn Tufariello; Lawrence W Leung; Mack Kuo; Christopher F Basler; David Alland; James C Sacchettini; Joel S Freundlich; William R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

8.  Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.

Authors:  Feng Wang; Paras Jain; Gulcin Gulten; Zhen Liu; Yicheng Feng; Krishna Ganesula; Alifiya S Motiwala; Thomas R Ioerger; David Alland; Catherine Vilchèze; William R Jacobs; James C Sacchettini
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

9.  Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.

Authors:  Kevin Pethe; Pablo Bifani; Jichan Jang; Sunhee Kang; Seijin Park; Sujin Ahn; Jan Jiricek; Juyoung Jung; Hee Kyoung Jeon; Jonathan Cechetto; Thierry Christophe; Honggun Lee; Marie Kempf; Mary Jackson; Anne J Lenaerts; Ha Pham; Victoria Jones; Min Jung Seo; Young Mi Kim; Mooyoung Seo; Jeong Jea Seo; Dongsik Park; Yoonae Ko; Inhee Choi; Ryangyeo Kim; Se Yeon Kim; SeungBin Lim; Seung-Ae Yim; Jiyoun Nam; Hwankyu Kang; Haejin Kwon; Chun-Taek Oh; Yoojin Cho; Yunhee Jang; Junghwan Kim; Adeline Chua; Bee Huat Tan; Mahesh B Nanjundappa; Srinivasa P S Rao; Whitney S Barnes; René Wintjens; John R Walker; Sylvie Alonso; Saeyeon Lee; Jungjun Kim; Soohyun Oh; Taegwon Oh; Ulf Nehrbass; Sung-Jun Han; Zaesung No; Jinhwa Lee; Priscille Brodin; Sang-Nae Cho; Kiyean Nam; Jaeseung Kim
Journal:  Nat Med       Date:  2013-08-04       Impact factor: 53.440

10.  Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis.

Authors:  Jozef Stec; Catherine Vilchèze; Shichun Lun; Alexander L Perryman; Xin Wang; Joel S Freundlich; William Bishai; William R Jacobs; Alan P Kozikowski
Journal:  ChemMedChem       Date:  2014-08-27       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.